Artificial intelligence is changing the way regulators evaluate medical devices, particularly where software functionality influences clinical decision-making or adapts over time. While software regulation is not new, machine learning introduces characteristics that traditional regulatory frameworks were not originally designed to address, including continuous learning, data dependency, and post-deployment variability.
This shift is particularly visible in Software as a Medical Device (SaMD), diagnostic platforms, clinical decision support systems, and predictive technologies where algorithmic outputs may directly influence patient care. In these contexts, regulators are increasingly focused not only on whether a device performs safely at the time of authorization, but whether the manufacturer can maintain ongoing control over performance, transparency, and change management throughout the product lifecycle.
The result is a broader transition away from static software oversight toward lifecycle-based governance models that place greater emphasis on monitoring, validation, documentation, and post-market accountability.
AI-enabled medical devices now span a broad range of technologies and risk classifications. Common applications include:
In many cases, the underlying concern is not simply that AI is being used, but that machine learning systems may behave differently depending on training data, deployment environment, or subsequent updates. Regulators increasingly distinguish between static models, where outputs remain fixed after deployment, and adaptive models capable of evolving over time. Importantly, adaptive functionality does not mean uncontrolled self-modification after deployment. Regulators are focused on whether future changes are bounded, validated, documented, and managed through appropriate change-control processes.
That distinction matters because adaptive systems complicate several established regulatory assumptions. Traditional medical device oversight was built around fixed functionality, controlled versioning, and predictable outputs. Machine learning-enabled systems introduce the possibility that performance characteristics may shift after authorization, requiring regulators to evaluate not only the device itself, but the manufacturer’s ability to govern ongoing changes.
Although terminology differs across jurisdictions, regulatory expectations are beginning to converge around several core principles: transparency, validation, lifecycle oversight, risk management, and human accountability.
FDA has taken the most operationally developed approach to AI-enabled medical devices to date. Rather than treating AI as a standalone regulatory category, FDA evaluates AI-enabled functionality within existing medical device frameworks, including 510(k), De Novo, and PMA pathways.
What distinguishes FDA’s approach is its emphasis on Total Product Lifecycle (TPLC) oversight. The agency’s guidance increasingly focuses on how manufacturers:
Particular attention has been placed on Predetermined Change Control Plans (PCCPs), which are intended to establish structured pathways for pre-specified future model updates without requiring entirely new submissions for every modification. A PCCP is not a blank cheque for continuous learning. It is a controlled mechanism for managing defined, validated, and documented changes within pre-established boundaries. This reflects an acknowledgment that adaptive systems cannot always be regulated effectively through static approval models alone.
Health Canada’s approach remains strongly aligned with international harmonization efforts through IMDRF, while increasingly adopting lifecycle principles similar to FDA.
Health Canada’s pre-market guidance for Machine Learning-Enabled Medical Devices (MLMDs) applies to Class II, III, and IV MLMD applications and places significant emphasis on:
Rather than focusing exclusively on algorithm performance, Health Canada increasingly evaluates whether manufacturers have implemented appropriate governance structures capable of maintaining safety and effectiveness over time.
This reflects a broader regulatory trend: AI oversight is becoming as much a quality systems issue as it is a software issue.
The European Union has approached AI-enabled medical devices through both the Medical Device Regulation (MDR) and the EU AI Act.
Under the EU framework, AI-enabled medical devices may also trigger obligations under the EU AI Act, particularly where the device falls within the high-risk framework based on its medical device classification and conformity assessment pathway.. These obligations may include:
Compared to FDA and Health Canada, the EU framework is generally more governance-heavy and legally structured, particularly regarding accountability and documentation.
One of the clearest regulatory shifts is the movement toward evaluating AI-enabled devices across their entire lifecycle rather than only at the point of authorization.
| Lifecycle Stage | Key Regulatory Focus | Primary AI Concern |
| Design & Development | Risk management and design controls | Poor model architecture or inadequate controls |
| Data Selection & Training | Dataset quality and representativeness | Bias and poor generalizability |
| Validation & Clinical Evidence | Performance verification and intended use | Weak or non-reproducible evidence |
| Regulatory Submission | Documentation and traceability | Lack of explainability or incomplete records |
| Transparency & Labeling | User understanding and limitations | Misleading claims or unclear outputs |
| Change Management | Controlled modifications and PCCPs | Unmanaged model drift |
| Post-Market Monitoring | Ongoing performance surveillance | Performance degradation over time |
| Cybersecurity & Data Protection | Data integrity and system resilience | Adversarial vulnerabilities or breaches |
The common thread across these stages is that regulators increasingly expect manufacturers to demonstrate ongoing control over systems that may evolve after deployment.
Although regulators are converging around core principles, important differences remain in how oversight is operationalized.
FDA’s framework is highly practical and operational, emphasizing lifecycle controls, planned modifications, and performance monitoring.
Health Canada’s framework is more principles-based and internationally aligned, relying heavily on risk management and harmonization initiatives.
The EU approach is broader from a governance perspective, incorporating legal obligations around AI oversight, transparency, and accountability that extend beyond traditional medical device review.
For manufacturers operating globally, this creates a growing need for harmonized internal governance capable of satisfying multiple regulatory expectations simultaneously.
Regulatory concern around AI-enabled medical devices extends well beyond whether a model produces accurate outputs under ideal conditions.
Several recurring themes now appear consistently across FDA, Health Canada, IMDRF, and international guidance documents.
Regulators increasingly expect manufacturers to demonstrate that model performance has been evaluated across relevant patient populations and demographic variables.
The concern is not simply statistical fairness, but whether insufficiently representative training data could create clinically significant disparities in performance.
Many AI systems function as “black boxes,” making it difficult for users to understand how outputs were generated.
Regulators increasingly view transparency as part of safety and effectiveness, particularly where clinical decisions may rely on algorithmic recommendations.
Unlike conventional software, machine learning systems may degrade or evolve over time due to new data, retraining, or environmental variation.
This creates growing emphasis on post-market monitoring, controlled updates, and structured change management processes.
AI systems rely heavily on data integrity and secure infrastructure. Weak governance around training data, access controls, or retraining processes may create both compliance and patient safety concerns.
As a result, cybersecurity expectations are becoming increasingly integrated into AI oversight.
Manufacturers developing AI-enabled medical devices are increasingly expected to demonstrate organizational maturity—not simply technical innovation. In practice, this means that AI governance is no longer just a software-development issue; it is becoming part of the safety case, the quality system, and the regulatory strategy.
Regulators are now evaluating whether companies have appropriate systems in place to govern:
This has significant operational implications because AI governance cannot be isolated within software development teams alone. It increasingly intersects with quality systems, regulatory affairs, clinical evaluation, cybersecurity, and post-market surveillance.
Organizations that approach AI as solely a technical issue may find themselves unprepared for the broader governance expectations now emerging across jurisdictions.
This is where many organizations underestimate the regulatory burden. AI governance is often treated as a technical workstream, but regulators are increasingly evaluating it as a cross-functional compliance issue. Regulatory affairs, quality assurance, clinical evidence, software development, cybersecurity, data governance, and post-market surveillance all need to connect.
For AI-enabled medical devices, regulatory readiness is not only about preparing a submission. It is about building the systems needed to support the device before, during, and after authorization.
One of the clearest regulatory trends globally is the movement toward lifecycle-based oversight models for AI-enabled technologies.
Frameworks such as Good Machine Learning Practice (GMLP), Total Product Lifecycle (TPLC) management, and Predetermined Change Control Plans (PCCPs) all reflect the same underlying principle: regulators increasingly expect manufacturers to demonstrate ongoing control over adaptive systems.
In practice, this means organizations should begin preparing for AI governance as a long-term operational requirement rather than a one-time submission exercise.
For companies developing or commercializing AI-enabled medical devices, the most important question is no longer simply whether the model performs well in a controlled development environment. The more practical question is whether the organization can demonstrate ongoing control over the model, the data, the intended use, the user interface, and future changes.
Manufacturers should be asking:
• Is the AI functionality clearly tied to the device’s intended use and risk classification?
• Has performance been validated across the relevant patient population and clinical context?
• Are the training, validation, and test datasets sufficiently representative and well documented?
• Can users understand the intended output, limitations, and appropriate level of reliance?
• Is there a clear process for monitoring model performance after deployment?
• Are future algorithm changes controlled through a defined change-management process?
• Does the quality system adequately address AI governance, software lifecycle controls, cybersecurity, clinical evaluation, and post-market surveillance?
These questions are increasingly central to regulatory readiness. A strong AI model may support innovation, but a strong governance framework is what makes that innovation defensible.
At dicentra, we work at the intersection of regulatory affairs, quality systems, clinical strategy, and medical device compliance—where the impact of AI is increasingly reshaping product development and oversight expectations.
As AI becomes more embedded into medical devices and Software as a Medical Device (SaMD), organizations are facing growing pressure to ensure that innovation remains aligned with evolving regulatory requirements.
We support companies by:
Our role is to help organizations move from AI concept to regulatory readiness. That includes assessing whether AI functionality is appropriately characterized, identifying the applicable regulatory pathway, supporting evidence and validation strategies, aligning quality-system controls with AI lifecycle expectations, and helping manufacturers prepare for post-market monitoring, change management, and long-term regulatory defensibility. Contact dicentra for support with AI-enabled medical devices, Software as a Medical Device (SaMD), and machine learning regulatory strategy.
Contact dicentra for support with artificial intelligence regulation in medical devices.